BioCentury
ARTICLE | Company News

Noven, JDS deal

July 16, 2007 7:00 AM UTC

NOVN will acquire JDS for $125 million in cash, plus the assumption of about $10 million in net liabilities. The specialty pharma company, which markets and develops products for psychiatry and women's health, gives NOVN a 55-person U.S. sales force. NOVN has three products marketed through a JV with Novartis AG (NVS; SWX:NOVN, Basel, Switzerland): Vivelle estradiol patch and Vivelle-Dot estradiol transdermal system to treat symptoms of menopause and prevent postmenopausal osteoporosis; and CombiPatch estradiol/norethindrone acetate patch to treat menopausal symptoms and hypoestrogenism. ...